The Tuberculosis Vaccines Pipeline: A New Path to the Same Destination?
Pipeline • 2015July 2015 By Mike Frick Call it a paradigm shift, a pivot, or a turn – tuberculosis (TB) vaccine research and development (R&D) is entering a period of basic science. After years of focusing on phase II clinical trials, some of the field’s largest players are now redirecting attention and resources to the beginning of…
Fit For Purpose: Antiretroviral Treatment Optimization
Pipeline • 2015July 2015 By Polly Clayden The most striking news since the 2014 Pipeline Report is from the START (Strategic Timing of AntiRetroviral Treatment) study.1 We now have evidence from a large, randomized, controlled trial to show that CD4 count is no longer a barrier to starting antiretroviral treatment (ART). START results mean that guidelines worldwide…
Governor Cuomo’s Ending the Epidemic Task Force Completes Plan to End AIDS in NY State by 2020
Statement / Press • 2015Today the Ending the Epidemic Task Force, convened by the New York State Department of Health (DOH) at the behest of Governor Andrew M. Cuomo, completed its comprehensive, rigorous, and unprecedented Plan to End AIDS in New York State by 2020.
Gilead: Stop Blocking Access to Hepatitis C Treatment
Statement / Press • 2015On the eve of pharmaceutical company Gilead Sciences’ annual shareholder meeting, thousands of people who have hepatitis C virus (HCV) and HCV/HIV coinfection, with their allies and physicians, have demanded that Gilead change its policies that deny access to treatment for millions of people in developing countries.
Governor Releases Blueprint to End AIDS in NYS by 2020
Statement / Press • 2015New York, NY– Governor Cuomo formally accepted the long-awaited Blueprint to End AIDS at a public event on Wednesday, marking an important step towards fulfilling his commitment to end AIDS in New York State.
Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries
Publication • 2015Liver disease from hepatitis C virus (HCV) is one of the leading causes of death around the world. At least 185 million people have been infected and almost 500,000 people die from it each year. The hope for eradicating HCV has recently gained new momentum: effective treatments reaching a 100 percent cure rate in clinical trials are now available.
Story: Doctors “Cure” HIV Patient with Cord Blood Transplant
Page • 2014November 2014 Examples of media coverage: Primer Paciente “Curado” del VIH por un Trasplante de Sangre de Cordón Umbilical – El Mundo, November 6, 2014 Doctors “Cure” HIV Patient with Blood Transplant – Local: Spain’s News in English, November 6, 2014 HIV Cure News 2014: Barcelona Doctors Believe They’ve Found Cure to AIDS-Causing Virus –…Fit for Purpose: Treatment Optimization
Pipeline • 2014July 2014 By Polly Clayden Since the 2013 Pipeline Report treatment optimization has continued to gain traction. Results from one of the key dose optimization trials ENCORE1—showing a lower dose of efavirenz (EFV) is non-inferior to the currently approved one— were published,1 and dolutegravir (DTG)—one of the most promising pipeline drugs for this purpose—was approved…
Preventive Technologies: Antiretroviral and Vaccine Development
Pipeline • 2014July 2014 By Tim Horn and Richard Jefferys The U.S. Food and Drug Administration (FDA) approval of co-formulated tenofovir DF and emtricitabine (Truvada) as preexposure prophylaxis (PrEP) has transformed the HIV prevention landscape, though perhaps more in theory than reality. Uptake of PrEP has been slow, including among men who have sex with men (MSM),…
Pharma Refuses to Ensure Access to Lifesaving Hepatitis C Treatment at Global Meeting
Statement / Press • 2014Thirty-eight activists from 22 countries joined forces at the first-ever Hepatitis C Virus (HCV) World Community Advisory Board (CAB) to demand equitable access to treatment for hepatitis C virus (HCV) from six multinational pharmaceutical companies.